WILMINGTON, Mass.--(BUSINESS WIRE)--
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has extended its longstanding integrated drug discovery alliance with Genentech, a member of the Roche Group.
“We are proud to work with Genentech to identify early-stage molecules that will ultimately result in innovative treatments for patients,” said John Montana, Executive Director, Integrated Drug Discovery at Charles River. “Our long-term collaboration with Genentech has been mutually beneficial for both companies. As our teams have demonstrated, when biotechs and CROs work together, they have the ability to enhance innovations in early discovery research.”
Through this alliance, Charles River provides Genentech early discovery services, including medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design, to help identify promising candidates for preclinical development.
Charles River and Genentech have engaged in an ongoing program since 2005, with the latest extension providing a three-year continuation. The program began with a single project involving medicinal chemistry, and has evolved over the past 11 years to a multi-disciplinary collaboration drawing on Charles River’s leading researchers in chemistry, biology and pharmacology.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161011005232/en/
